Jiangsu Recbio Technology Co., Ltd. (HKG:2179)

Market Cap	2.52B -36.7%
Revenue (ttm)	14.16M -52.9%
Net Income	-679.25M
EPS	-1.28
Shares Out	616.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,700
Open	n/a
Previous Close	4.080
Day's Range	n/a
52-Week Range	3.400 - 9.580
Beta	-0.18
RSI	37.96
Earnings Date	Mar 24, 2026

About Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 507
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2179

Financial Performance

In 2025, Jiangsu Recbio Technology's revenue was 12.73 million, a decrease of -52.88% compared to the previous year's 27.01 million. Losses were -610.39 million, 9.49% more than in 2024.

Financial numbers in CNY